Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/IKAP stock hub

FRA/IKAP has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/IKAPis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.7B

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/IKAPFRA/IKAP

—

Loading chart…

In the news

Latest news · FRA/IKAP

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E14.3

P25 n/aP50 n/aP75 n/a

Trailing P/E6.4

P25 n/aP50 n/aP75 n/a

ROE65

P25 n/aP50 n/aP75 n/a

ROIC66.3

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/IKAP market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

199

Groups with data

Currency

USD

Showing 199 of 199 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Canada
Country code	DE
Employees	128
Employees Change	-170%
Employees Change Percent	-56.67
Enterprise value	EUR 1.4B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 1.7B
Price	EUR 12.69
Price currency	EUR
Rev Per Employee	2,021,181.67x
Sic	2836
Symbol	fra/IKAP
Website	https://www.auriniapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	15.54%
EV Earnings	5.42x
EV/EBIT	12.28x
EV/EBITDA	10.67x
EV/FCF	9.69x
EV/Sales	5.53x
FCF yield	8.69%
Forward P/E	14.32x
P/B ratio	3.38x
P/E ratio	6.43x
P/S ratio	6.43x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	45.02%
EBITDA Margin	51.53%
FCF margin	55.87%
Gross margin	78.27%
Gross Profit	EUR 202.5M
Gross Profit Growth	17.08%
Gross Profit Growth Q	15.14%
Gross Profit Growth3 Y	37.74%
Net Income	EUR 258.6M
Net Income Growth	4,893.08%
Net Income Growth Q	14,651.16%
Pretax Margin	44.83%
Profit Margin	99.97%
Profit Per Employee	EUR 2M
ROA	13.66
Roa5y	-6.82
ROCE	21.07
ROE	64.98
Roe5y	-4.75
ROIC	66.31
Roic5y	-286.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	18.7%
Cagr15y	5.99%
Cagr1y	80.28%
Cagr3y	5.85%
Cagr5y	8.73%
EPS Growth	5,075
EPS Growth Q	15,073.2
FCF Growth	206.99%
FCF Growth Q	52.84%
OCF Growth	205.62%
OCF Growth Q	51.65%
Revenue Growth	20.38x
Revenue Growth Q	28.81x
Revenue Growth3 Y	28.3x
Revenue Growth5 Y	41.38x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.49
Assets	EUR 627.9M
Cash	EUR 328.3M
Current Assets	EUR 417.2M
Current Liabilities	EUR 79.5M
Debt	EUR 59.5M
Debt EBITDA	EUR 0.44
Debt Equity	EUR 0.12
Debt FCF	EUR 0.41
Equity	EUR 492.3M
Interest Coverage	31.42
Liabilities	EUR 135.6M
Long Term Assets	EUR 210.8M
Long Term Liabilities	EUR 56.1M
Net Cash	EUR 268.8M
Net Cash By Market Cap	EUR 16.15
Net Cash Growth	15.79%
Net Debt EBITDA	EUR -2.02
Net Debt Equity	EUR -0.55
Net Debt FCF	EUR -1.86
Tangible Book Value	EUR 489.2M
Tangible Book Value Per Share	EUR 3.74

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.55
Inventory Turnover	1.4
Net Working Capital	EUR 28.9M
Quick ratio	4.95
Working Capital	EUR 341.4M
Working Capital Turnover	EUR 0.69

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	5.13%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	455.12%
1Y total return	80.2%
200-day SMA	11.79
3Y total return	18.6%
50-day SMA	12.88
50-day SMA vs 200-day SMA	50over200
5Y total return	51.98%
All Time High	29.86
All Time High Change	-57.5%
All Time High Date	2021-10-25
All Time Low	0.05
All Time Low Change	25,280%
All Time Low Date	2012-12-21
ATR	0.36
Ch YTD	-4.12
High	12.69
High52	14.27
High52 Date	2025-12-01
High52ch	-11.07%
Low	12.69
Low52	6.19
Low52 Date	2025-07-03
Low52ch	105.01%
Ma50ch	-1.44%
Price vs 200-day SMA	7.68%
RSI	43.61
RSI Monthly	63.06
RSI Weekly	57.31
Sharpe ratio	1.37x
Sortino ratio	2.54
Total Return	5.13%
Tr YTD	-4.12
Tr15y	139.43%
Tr1m	-5.79%
Tr1w	-5.01%
Tr3m	5.4%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 116.5M
Operating Income Growth	828.7
Operating Income Growth Q	451.8
Operating margin	45.02

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	127,575,799%
Net Borrowing	-11,138,828.8
Shares Insiders	0.96%
Shares Institutions	62.34%
Shares Qo Q	1.58%
Shares Yo Y	-5.13%
Short Ratio	8.21

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 129.6M
Average Volume	5.25x
Bv Per Share	3.76
CAPEX	EUR -237,640
Ch10y	455.1
Ch15y	139.4
Ch1m	-5.79
Ch1w	-5.01
Ch1y	80.2
Ch3m	5.4
Ch3y	18.6
Ch5y	51.98
Ch6m	1.4
Change	-6.76%
Change From Open	0
Close	13.61
Days Gap	-6.76
Depreciation Amortization	16,492,012.9
Earnings Date	2026-05-12
EBIT	EUR 116.5M
EBITDA	EUR 133.3M
EPS	EUR 1.89
F Score	5
FCF	EUR 144.5M
FCF EV Yield	10.32x
Financing CF	-95,800,223
Fiscal Year End	December
Founded	1,993
Graham Number	12.9079
Graham Upside	1.72
Income Tax	EUR -142.7M
Investing CF	-71,014,524
Is Primary Listing	0
Last Earnings Date	2026-02-26
Last Report Date	2025-12-31
Last Split Date	2013-10-23
Last Split Type	Reverse
Ma150	12.41
Ma150ch	2.3%
Ma20	13.48
Ma20ch	-5.89%
Net CF	-22,046,766
Next Earnings Date	2026-05-12
Open	12.69
P FCF Ratio	11.51
P OCF Ratio	11.49
Ppne	67,474,032.3
Price Date	2026-05-08
Price EBITDA	EUR 12.48
Ptbv Ratio	3.4
Relative Volume	10.55x
Revenue	258,711,254x
SBC By Revenue	5.77x
Share Based Comp	14,935,773
Tax By Revenue	-55.14x
Tr6m	1.4%
Volume	0
Z Score	6.57

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/IKAP pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/IKAP stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/IKAP?

Insider, institutional, and short-interest positioning.

Institutional ownership

+62.3%

Share of float held by funds and institutions

Insider ownership

+1.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/IKAP momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

43.6

Neutral momentum band

Price vs 200-day MA

+7.7%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.37

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/IKAP

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/IKAP stock rating?

fra/IKAP is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/IKAP analysis?

The full report lives at /stocks/fra/IKAP/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/IKAP?

The latest report frames fra/IKAP around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/IKAP page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.